Immunoprecise Antibodies Ltd (IPA) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Jan 31 2026 to Jan 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Immunoprecise Antibodies Ltd   (NASDAQ: IPA)

Immunoprecise Antibodies Ltd 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Immunoprecise Antibodies Ltd in the third quarter 2026?
Immunoprecise Antibodies Ltd recorded a cumulative net loss of $-9 million during 12 months ending in the third quarter 2026, resulting in a negative return on equity (ROE) of -58.58%.

Within the Major Pharmaceutical Preparations industry 248 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2025 from to 3648.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jan 31 2026)
III. Quarter		 (Oct 31 2025)
II. Quarter		 (Jul 31 2025)
I. Quarter		 (Apr 30 2025)
IV. Quarter		 (Jan 31 2025)
III. Quarter
Y / Y Equity Change -0.85 % -51.36 % -34.52 % -61.35 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -9 -21 -40 -40 -38
Return On Equity (TTM) -58.58 % -137.89 % -211.77 % -190.32 % -137.08 %
IPA's Total Ranking # 3648 # # # #
Equity (TTM) in Millions 17 13 15 17 17
Seq. Equity Change 35.4 % -15.65 % -12.44 % -0.85 % -33.58 %
Seq. Net Income Change - - - - -

Back to IPA Management Effectiveness >> IPA's 5 Years Annual ROE >> Compare IPA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 249
Sector # 572
Overall # 3648

Return On Equity Statistics
High Average Low
-80.12 %
-80.12 %
-80.12 %
(Apr 30 2024)  





IPA Annual Return On Equity (Apr 30 2025)
2025		 (Apr 30 2024)
2024		 (Apr 30 2023)
2023		 (Apr 30 2022)
2022		 (Apr 30 2020)
2021
Total Equity in Millions 17 26 44 59 11
Y / Y Equity Change -34.14 % -41.32 % -24.71 % 442.27 % -
Net Income in Millions -22 -21 -20 -13 -4
Y / Y Net Income Change - - - - -
Return On Equity -126.84 % -80.12 % -45.95 % -22.65 % -34.14 %

Back to IPA Management Effectiveness >> IPA's 5 Years Annual ROE >> Compare IPA ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IPA's' Return on Equity at Yahoo Finance
IPA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IPA's Competitors
Subscribers only: Roe for Immunoprecise Antibodies Ltd 's Suppliers
Subscribers only: Return On Equity for IPA's Customers




Companies with similar Return On Equity at Jan 31 2026, within Healthcare Sector ROE

Date modified: 2026-09-18T17:05:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.